Market Overview

UPDATE: SunTrust Robinson Humphrey Reiterates on Hologic as Deterioration Story Gains Momentum

Related HOLX
Hologic Poised on Solid Quarterly Growth Amid Several Odds - Analyst Blog
Hologic's 3D Mammography Improves Breast Cancer Screening - Analyst Blog

In a report published Tuesday, SunTrust Robinson Humphrey analyst Amit Hazan reiterated a Reduce rating on Hologic (NASDAQ: HOLX), but lowered the price target from $17.00 to $15.00.

In the report, SunTrust Robinson Humphrey noted, “New guidance for FY14 reflects the reality of deteriorating end markets and only the beginning of significant margin pressure in the years ahead. Declining EBITDA and a two year delay in leverage target guidance are similarly of high concern. Hopes for a return to growth by FY15 look entirely unrealistic to us, and we lower our PT from $17 to $15 in order to reflect what we view as notably greater risk.”

Hologic closed on Monday at $22.90.

Posted-In: Amit Hazan SunTrust Robinson HumphreyAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (HOLX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free